Metraipolis › archive › dc_f3fa671e61a2

Phase 1 study of ceralasertib, an ATR kinase inhibitor, in combination with durvalumab in patients with recurrent or metastatic NSCLC or HNSCC — Europe PMC PMID:41917211

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41917211
DOI
10.1038/s41416-[numero omesso]-y
License (as archived)
solo-consultazione
Archived
2026-11-03T15:28:21.553Z
SHA-256 of the archived text
a9b60959088a2d4e715516f48e4d1d5d2e45fc5ef357354e1242e23a9814a260
Stable URL of this page
https://metraipolis.com/documento/dc_f3fa671e61a2

How to cite

Phase 1 study of ceralasertib, an ATR kinase inhibitor, in combination with durvalumab in patients with recurrent or metastatic NSCLC or HNSCC — Europe PMC PMID:41917211 — Europe PMC (en), https://europepmc.org/article/MED/41917211 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_f3fa671e61a2 (Metraipolis archive dc_f3fa671e61a2, sha256 a9b60959088a2d4e715516f48e4d1d5d2e45fc5ef357354e1242e23a9814a260)
BibTeX
@misc{dcf3fa671e61a2,
  title = {Phase 1 study of ceralasertib, an ATR kinase inhibitor, in combination with durvalumab in patients with recurrent or metastatic NSCLC or HNSCC — Europe PMC PMID:41917211},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41917211},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_f3fa671e61a2; sha256 a9b60959088a2d4e715516f48e4d1d5d2e45fc5ef357354e1242e23a9814a260},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41917211. Agents can read the archived copy with the MCP tool read_document.